Search Results for 'capacity'

Contract Service Directory Companies

View All Buyers Guide Companies »

• APIs | Breaking News | Excipients | Industry News
  

  Amino GmbH to Double Production Capacity

  Investing $35 million in new German facility; plans include expanding market presence in the U.S.

  02.13.20
  

  ---

• 

  Capacity Management Within Functional Service Partnerships

  Looking at the advantages and disadvantages of moving capacity management from sponsors to their FSP vendors.

  Brian Ford and Timothy King, PPD FSP 01.28.20
  

  ---

• APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
  

  Heraeus Expands Cancer Therapy API Capacity

  Adds production line at German HQ.

  11.22.19
  

  ---

• cGMP Manufacture | Fill/Finish | Industry News | Parenterals
  

  Berkshire Sterile Manufacturing Expands Capacity

  To add a third isolator line with the ability to fill at a rate of 3000 units/hour

  08.16.19
  

  ---

• Breaking News | cGMP Manufacture | Fill/Finish | Industry News
  

  Catalent to Expand Biologics Capacity and Capabilities

  To invest $200 million in its manufacturing sites in Madison, WI and Bloomington, IN

  01.07.19
  

  ---

• Bio News | Biologics, Proteins, Vaccines | Biosimilars | Breaking News | cGMP Manufacture | Industry News
  

  REPORT: Biopharma Mfg. Capacity and Production

  222 biopharma companies surveyed plus130 industry vendors and direct suppliers of materials

  08.17.18
  

  ---

• Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Logistics | Lyophilization | Methods Development | Process Development | QA/QC | Serialization | Supply Chain | Validation

  CMOs Facing Significant Capacity Constraints

  Downstream purification creating chronic problems

  Eric S. Langer, BioPlan Associates 06.02.15
  

  ---

• Biosimilars | cGMP Manufacture | Toxicology

  Too Much CMO Capacity?

  A decade ago, there were dire concerns that the biopharmaceutical industry was headed for a severe crisis. There was, it was thought, inadequate mammalian manufacturing capacity to support the development pipeline. In particular, fears grew about sho…

  Eric A. Langer, BioPlan Associates 03.07.14
  

  ---

• Biosimilars | Validation
  

  Bio-CMO Capacity Constraints

  What they’re doing about them

  Eric Langer, BioPlan Associates 09.05.13
  

  ---

• Vials
  

  Capacity Utilization & Capacity Constraints

  Trends and differences in the U.S. & Western Europe

  Eric S. Langer 05.04.09
  

  ---